본문 바로가기
KERD
논문KCI 등재

졸피뎀 유발 복합 수면 행동

Zolpidem-Induced Complex Sleep-Related Behavior

2

조회

0

다운로드

1

인용

0

참고문헌

키워드

주제분류정신과학

초록

Zolpidem is a non-benzodiazepine hypnotic agent as an agonist of the GABAA benzodiazepine receptor. Zolpidem is considered to have lower abuse and dependence potential than benzodiazepines, and is widely used for the shortterm treatment of insomnia. However, the complex sleep-related behaviors caused by zolpidem have recently emerged as a major challenge. The purpose of this study was to review zolpidem-induced complex sleep-related behaviors and one of the most commonly reported behaviors, sleep-related eating disorder. The risk factors for these complex sleep-related behaviors are female sex, advanced age, daily doses of 10 mg or more, alcohol consumption, and comorbid medical illnesses. Strategies for managing zolpidem-induced complex sleep-related behaviors; discontinuing the use of zolpidem, switching to different sedative-hypnotic drugs, treating patients with other classes of medications, and using non-pharmacological treatment strategies for patients with sleep disorder. These strategies should also include examining drug regimens for potential drug interactions that may predispose patients to experiencing complex behaviors, administering zolpidem appropriately, and selecting patients more carefully for treatment in terms of their likelihood of experiencing medication-related adverse reactions. In conclusion, complex sleep-related behaviors related to zolpidem should be considered adverse drug reactions prior to drug prescription, and a patient’s potential risk factors should be evaluated. Physicians should pay attention to the occurrence of abnormal behavioral adverse effects related to zolpidem.

Abstract

Zolpidem is a non-benzodiazepine hypnotic agent as an agonist of the GABAA benzodiazepine receptor. Zolpidem is considered to have lower abuse and dependence potential than benzodiazepines, and is widely used for the shortterm treatment of insomnia. However, the complex sleep-related behaviors caused by zolpidem have recently emerged as a major challenge. The purpose of this study was to review zolpidem-induced complex sleep-related behaviors and one of the most commonly reported behaviors, sleep-related eating disorder. The risk factors for these complex sleep-related behaviors are female sex, advanced age, daily doses of 10 mg or more, alcohol consumption, and comorbid medical illnesses. Strategies for managing zolpidem-induced complex sleep-related behaviors; discontinuing the use of zolpidem, switching to different sedative-hypnotic drugs, treating patients with other classes of medications, and using non-pharmacological treatment strategies for patients with sleep disorder. These strategies should also include examining drug regimens for potential drug interactions that may predispose patients to experiencing complex behaviors, administering zolpidem appropriately, and selecting patients more carefully for treatment in terms of their likelihood of experiencing medication-related adverse reactions. In conclusion, complex sleep-related behaviors related to zolpidem should be considered adverse drug reactions prior to drug prescription, and a patient’s potential risk factors should be evaluated. Physicians should pay attention to the occurrence of abnormal behavioral adverse effects related to zolpidem.

참고문헌 (73)

  1. Hajak G, "Abuse and dependence potential for the non-benzodiazepine hypnotics zolpidem and zopiclone : a review of case reports and epidemiological data", Addiction, 98, pp.1371~1378 (2003)
  2. Monti JM, "Zolpidem’s use for insomnia", Asian J Psychiatr, 25, pp.79~90 (2017)
  3. Dolder CR, "Hypnosedative-induced complex behaviours: incidence, mechanisms and management", CNS Drugs, 22, pp.1021~1036 (2008)
  4. "FDA requires stronger warnings about rare but serious incidents related to certain prescription insomnia medicines" (2019)[URL]
  5. "Standards for safe use of zolpidem" (2020)[URL]
  6. Pérez-Díaz H, "Zolpidem-induced sleep-related behavioural disorders", Neurologia, 25, pp.491~497 (2010)
  7. Hoque R, "Zolpidem-induced sleepwalking, sleep related eating disorder, and sleep-driving:fluorine-18-flourodeoxyglucose positron emission tomography analysis, and a literature review of other unexpected clinical effects of zolpidem", J Clin Sleep Med, 5, pp.471~476 (2009)
  8. Morgenthaler TI, "Amnestic sleep-related eating disorder associated with zolpidem", Sleep Med, 3, pp.323~327 (2002)
  9. Najjar M, "Zolpidem and amnestic sleep related eating disorder", J Clin Sleep Med, 3, pp.637~638 (2007)
  10. Thara R, "Adverse events after zolpidem intake", Indian J Psychiatry, 43, pp.85~86 (2001)
  11. Gibson CE, "Zolpidem-associated parasomnia with serious self-injury : a shot in the dark", Psychosomatics, 52, pp.88~91 (2011)
  12. Poceta JS, "Zolpidem ingestion, automatisms, and sleep driving: a clinical and legal case series", J Clin Sleep Med, 7, pp.632~638 (2011)
  13. Tsai MJ, "Compulsive activity and anterograde amnesia after zolpidem use", Clin Toxicol, 45, pp.179~181 (2007)
  14. Sidana A, "Zolpidem induced delirium", Indian J Psychiatry, 44, pp.398~ (2002)
  15. Ansseau M, "Psychotic reactions to zolpidem", Lancet, 339, pp.809~ (1992)
  16. Iruela LM, "More on zolpidem side-effects", Lancet, 342, pp.1495~1496 (1993)
  17. Kito S, "Visual hallucinations and amnesia associated with zolpidem triggered by fluvoxamine : a possible interaction", Int Psychogeriatr, 18, pp.749~751 (2006)
  18. Huang CL, "Zolpidem-induced distortion in visual perception", Ann Pharmacother, 37, pp.683~686 (2003)
  19. Inagaki T, "Adverse reactions to zolpidem: case reports and a review of the literature. Prim Care Companion", J Clin Psychiatry, 12 (2010)
  20. Markowitz JS, "Zolpidem and hallucinations", Ann Emerg Med, 29, pp.300~301 (1997)
  21. Tsai JH, "Zolpidem-induced amnesia and somnambulism : rare occurrences", Eur Neuropsychopharmacol, 19, pp.74~76 (2009)
  22. Ben-Hamou M, "Spontaneous adverse event reports associated with zolpidem in Australia 2001-2008", J Sleep Res, 20, pp.559~568 (2011)
  23. Le Bon O, "Total absence of recall of discussion occurred shortly after ingestion of 10mg zolpidem", Pharmacopsychiatry, 42, pp.126~127 (2009)
  24. Machado C, "Zolpidem arousing effect in persistent vegetative state patients: autonomic, EEG and behavioral assessment", Curr Pharm Des, 20, pp.4185~4202 (2014)
  25. Tassinari C, "Central pattern generators for a common semiology in fronto-limbic seizures and in parasomnias. A neuroethologic approach", Neurol Sci, 26, pp.s225~32 (2005)
  26. Yuste R, "The cortex as a central pattern generator", Nat Rev Neurosci, 6, pp.477~483 (2005)
  27. Juszczak GR, "Serotonergic hypothesis of sleepwalking", Med Hypotheses, 64, pp.28~32 (2005)
  28. Juszczak GR, "Desensitization of GABAergic receptors as a mechanism of zolpidem-induced somnambulism", Med Hypotheses, 77, pp.230~233 (2011)
  29. Yang W, "One rare side effect of zolpidem-sleepwalking : a case report", Arch Phys Med Rehabil, 86, pp.1265~1266 (2005)
  30. Feinberg I, "Effects of hypnotics on the sleep EEG of healthy young adults : new data and psychopharmacologic implications", J Psychiatr Res, 34, pp.423~438 (2000)
  31. Cubała WJ, "Sleep related amnestic behaviors due to zolpidem", Klinik Psikofarmakol Bülteni, 24, pp.188~194 (2014)
  32. Salvà P, "Clinical pharmacokinetics and pharmacodynamics of zolpidem. Therapeutic implications", Clin Pharmacokinet, 29, pp.142~153 (1995)
  33. Chen CS, "Clinical correlates of zolpidem-associated complex sleep-related behaviors : age effect", J Clin Psychiatry, 75, pp.e1314~e1318 (2014)
  34. Cubała WJ, "Zolpidem pharmacokinetics and pharmacodynamics in metabolic interactions involving CYP3A : sex as a differentiating factor", Eur J Clin Pharmacol, 66, pp.955~ (2010)
  35. Mallampalli MP, "Exploring sex and gender differences in sleep health: a society for women’s health research report", J Womens Health (Larchmt), 23, pp.553~562 (2014)
  36. Mittal N, "Zolpidem for insomnia: a double-edged sword. A systematic literature review on zolpidem-induced complex sleep behaviors", Indian J Psychol Med, pp.0253717621992372~ (2021)
  37. Wilkinson CJ, "The abuse potential of zolpidem administered alone and with alcohol", Pharmacol Biochem Behav, 60, pp.193~202 (1998)
  38. Chan LN, "Pharmacokinetic and pharmacodynamic drug interactions with ethanol(alcohol)", Clin Pharmacokinet, 53, pp.1115~1136 (2014)
  39. Lovinger DM, "Tonic for what ails us? high-affinity GABAA receptors and alcohol", Alcohol, 41, pp.139~143 (2007)
  40. Sattar SP, "Somnambulism due to probable interaction of valproic acid and zolpidem", Ann Pharmacother, 37, pp.1429~1433 (2003)
  41. Harazin J, "Zolpidem tartrate and somnambulism", Mil Med, 164, pp.669~670 (1999)
  42. Morgenthaler T, "Practice parameters for the psychological and behavioral treatment of insomnia: an update. An american academy of sleep medicine report", Sleep, 29, pp.1415~1419 (2006)
  43. Riemann D, "European guideline for the diagnosis and treatment of insomnia", J Sleep Res, 26, pp.675~700 (2017)
  44. Bennett D., "Cognitive-behavioral therapy for insomnia (CBT-I). Sleep Medicine and Mental Health", pp.47~66 (2020), Springer
  45. Rash JA, "A meta-analysis of mindfulness-based therapies for insomnia and sleep disturbance : moving towards processes of change", Sleep Med Clin, 14, pp.209~233 (2019)
  46. Toner LC, "Central nervous system side effects associated with zolpidem treatment", Clin Neuropharmacol, 23, pp.54~58 (2000)
  47. Ho T, "Sleeprelated eating disorder associated with zolpidem : cases compiled from a literature review", Sleep Medicine, X, pp.100019~ (2020)
  48. Kintz P, "Drug-facilitated sexual assault and analytical toxicology : the role of LC-MS", MS a case involving zolpidem, 2005, pp.12, 36~41
  49. Canaday BR, "Amnesia possibly associated with zolpidem administration", Pharmacotherapy, 16, pp.687~689 (1996)
  50. American Academy of Sleep Medicine, "The International Classification of Sleep Disorders" (2014), American Academy of Sleep Medicine
  51. Chiang A, "Report of two cases where sleep related eating behavior occurred with the extended-release formulation but not the immediate-release formulation of a sedative-hypnotic agent", J Clin Sleep Med, 4, pp.155~156 (2008)
  52. Dang A, "Zolpidem induced nocturnal sleep-related eating disorder(NSRED)in a male patient", Int J Eat Disord, 42, pp.385~386 (2009)
  53. Miranda M, "Zolpidem induced sleep related eating disorder", Rev Med Chil, 138, pp.1067~1069 (2010)
  54. Yun CH, "Zolpidem-induced sleep-related eating disorder", J Neurol Sci, 288, pp.200~201 (2010)
  55. Wing YK, "Sleep-related eating disorder and zolpidem : an open interventional cohort study", J Clin Psychiatry, 71, pp.653~656 (2010)
  56. Nzwalo H, "Sleep-related eating disorder secondary to zolpidem", BMJ Case Rep (2013)
  57. Kim HK, "Zolpidem-induced compulsive evening eating behavior", Clin Neuropharmacol, 36, pp.173~174 (2013)
  58. 박영민, "Zolpidem Induced Sleep-related Eating and Complex Behaviors in a Patient with Obstructive Sleep Apnea and Restless Legs Syndrome", Clinical Psychopharmacology and Neuroscience, 14(3), pp.299~301 (2016), 대한정신약물학회
  59. Park YM, "Zolpidem-induced sleep-related eating disorder", Chronobiol Med, 1, pp.111~114 (2019)
  60. Furuhashi Y, "Sleep related eating disorder as an unexpected effect of zolpidem", Neurosci Med, 10, pp.75~ (2019)
  61. Oliveira L, "Pharmacological and electrical stimulation in chronic disorders of consciousness : new insights and future directions", Brain Inj, 25, pp.315~327 (2011)
  62. Du B, "Zolpidem arouses patients in vegetative state after brain injury : quantitative evaluation and indications", Am J Med Sci, 347, pp.178~182 (2014)
  63. Winkelman JW, "Sleep-related eating disorder and night eating syndrome: sleep disorders, eating disorders, or both?", Sleep, 29, pp.876~877 (2006)
  64. Inoue Y, "Sleep-related eating disorder and its associated conditions", Psychiatry Clin Neurosci, 69, pp.309~320 (2015)
  65. Howell MJ, "A review of nighttime eating disorders", Sleep Med Rev, 13, pp.23~34 (2009)
  66. Winkelman JW, "Clinical and polysomnographic features of sleep-related eating disorder", J Clin Psychiatry, 59, pp.14~19 (1998)
  67. Winkelman JW, "The prevalence of sleep-related eating disorder in psychiatric and non-psychiatric populations", Psychol Med, 29, pp.1461~1466 (1999)
  68. 조재욱, "수면관련섭식장애 1례", Journal of sleep medicine, 5(2), pp.100~102 (2008), 대한수면연구학회
  69. Schenck CH, "Additional categories of sleep-related eating disorders and the current status of treatment", Sleep, 16, pp.457~466 (1993)
  70. Vetrugno R, "Nocturnal eating : sleep-related eating disorder or night eating syndrome? A videopolysomnographic study", Sleep, 29, pp.949~954 (2006)
  71. Provini F, "A pilot double-blind placebo-controlled trial of low-dose pramipexole in sleep-related eating disorder", Eur J Neurol, 12, pp.432~436 (2005)
  72. Winkelman JW, "Efficacy and tolerability of open-label topiramate in the treatment of sleep-related eating disorder : a retrospective case series", J Clin Psychiatry, 67, pp.1729~1734 (2006)
  73. "Questions and answers:Risk of nextmorning impairment after use of insomnia drugs; FDA requires lower recommended doses for certain drugs containing zolpidem (ambien, ambien CR, edluar, and zolpimist)" (2018)[URL]

관련 논문AI추천

이 간행물의 다른 논문 (3건)